A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing
regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.